Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate

Journal of Virology

Volumn 72, Issue 10, 1998, Pages 7941-7949

  Julias, John G ^a,b   Pathak, Vinay K ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; HYDROXYUREA; THYMIDINE; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; GENETIC VARIABILITY; HELPER CELL; MURINE LEUKEMIA VIRUS; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; RETROVIRUS; REVERSE TRANSCRIPTION; TARGET CELL; VIRUS REPLICATION;

EID: 0031717603     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.10.7941-7949.1998     Document Type: Article

References (64)

1. Bebenek, K., J. Abbots, J. D. Roberts, S. H. Wilson, and T. A. Kunkel. 1989. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J. Biol. Chem. 264:16948-16956.
2. Birion, F., F. Lucht, D. Peyramond, A. Fresard, T. Vallet, F. Nugire, J. Grange, S. Malley, F. Hamedi-Sangsari, and J. Vila. 1996. Pilot clinical trial of the combination of hydroxyurca and didanosine in HIV-1 infected individuals. Antiviral Res. 29:111-113.
3. Cepko, C. 1992. XGAL staining of cultured cells, p. 9.11.9-9.11.12. In F. M. Ausuhel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology. Greene Publishing Associates and Wiley Interscience, New York. N. Y.
4. Coffin. J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
5. Cohcn, A., J. Barankiewicz, H. M. Lederman, and E. W. Gelfand. 1983. Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyrihonuclcotide metabolism. J. Biol. Chem. 258:12334-12340.
6. Davies, M. V., and R. J. Kaufman. 1992. The sequence context of the initiation codon in the encephalomyocarditis virus leader modulates efficiency of internal translation initiation. J. Virol. 66:1924-1932.
7. El-Farrash. M. A., M. J. Kuroda, T. Kitazaki, T. Masuda, K. Kato, M. Hatanaka, and S. Harada. 1994. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J. Virol. 68:233-239.
8. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
9. Frick, L. W., D. J. Nelson, M. H. St. Clair, P. A. Furman, and T. A. Krenitsky. 1988. Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem. Biophys. Res. Commun. 154:124-129.
10. Gao, W.-Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 90: 8925-8928.
11. Gao, W.-Y., D. G. Johns, and H. Mitsuya. 1994. Enzymatic assay for quantification of dcoxynucleoside triphosphates in human cells exposed to antiretroviral 2′,3′-dideoxynucleosides. Anal. Biochem. 222:116-122.
12. Gao, W.-Y., D. G. Johns, and H. Mitsuya. 1994. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46:767-772.
13. Giacca, M., S. Zanussi, M. Comar, C. Simonelli, E. Vaccher, P. de Paoli, and U. Tirelli. 1996. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J. Infect. Dis. 174:204-209.
14. Glickman, B. W., V. A. Saddi, and J. Curry. 1994. Spontaneous mutations in mammalian cells. Mutat. Res. 304:19-32.
15. Goulaouic. H., F. Subra, J. F. Mouscadet, S. Carteau, and C. Auclair. 1994. Exogenous nucleosides promote the completion of MoMLV DNA synthesis in GO-arrested Balb c/3T3 fibroblasts. Virology 200:87-97.
16. Gritz, L., and J. Davies. 1979. Plasmid encoded hygromycin-b resistance: the sequence of hygromycin b phosphotransferase and its expression. Gene 25: 179-188.
17. Gu, Z., Q. Gao, X. Li, M. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
18. Hao, Z., D. A. Cooney, N. R. Hartman, C. F. Perno, A. Fridland, A. L. De Vico, M. G. Sarngadharan, S. Broder, and D. G. Johns. 1988. Factors determining the activity of 2′,3′ dideoxynucleosidcs in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol. 34:431-435.
19. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
20. Hu. W.-S., and H. M. Temin. 1990. Genetic consequences of packaging two RNA genomes in one retroviral particle: pscudodiploidy and a high rate of genetic recombination. Proc. Natl. Acad. Sci. USA 87:1556-1560.
21. Jang, S., H. Krausslich, M. J. H. Nicklin, G. Duke, A. Palmenberg, and E. Wimmer. 1988. A segment of the 5′ nontranslated region of enccphalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62:2636-2643.
22. Japour. A. J., S. Welles, R. T. D'Aquilla, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reichelderfer, J. O. Kahn, C. S. Crumpacker, and D. R. Kuritzkes. 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J. Infect. Dis. 171:1172-1179.
23. Ji. J., and L. A. Loeh. 1992. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry 31:954-958.
24. Jorgensen, R. A., S. J. Rothstein, and W. J. Reznikoff. 1979. A restriction enzyme cleavage map of Tn5 and location of a region encoding neomycin resistance. Mol. Gen. Genet. 177:65-72.
25. Julias, J. G., T. Kim, G. Arnold, and V. K. Pathak. 1997. The antiretrovirus drug 3′-azido-3′-deoxythymidine increases the retrovirus mutation rate. J. Virol. 71:4254-4263.
26. Kawai, S., and M. Nishizawa. 1984. New procedures for DNA transfection with polycatron and dimethyl sulfoxide. Mol. Cell. Biol. 4:1172-1174.
27. Kim, T., R. A. Mudry, Jr., C. A. Rexrode II, and V. K. Pathak. 1996. Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication. J. Virol. 70:7594-7602.
28. Kunz, B. A., and S. E. Kohalmi. 1991. Modulation of mutagenesis by deoxyribonucleotide levels. Annu. Rev. Genet. 25:339-359.
29. Larder, B. A., G. Darby, and D. D. Richman. 1989 HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
30. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
31. Loeb, L. A., and T. A. Kunkel. 1982. Fidelity of DNA synthesis. Annu. Rev. Biochem. 51:429-157.
32. Lori, F., A. G. Malykh, A. Foli, R. Maserati, A. De Antoni, L. Minoli, D. Padrini, A. Degli Antoni, E. Barchi, H. Jessen, M. A. Wainberg, R. C. Gallo, and J. Lisziewicz. 1997. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res. Hum. Retroviruses 13:1403-1409.
33. Mansky, L. M., and H. M. Temin. 1994. Lower mutation rate of bovine leukemia virus relative to that of spleen necrosis virus. J. Virol. 68:494-499.
34. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
35. Martinez, M. A., J.-P. Vartanian, and S. Wain-Hobson. 1994. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl. Acad. Sci. USA 91:11787-11791.
36. Meuth, M. 1989. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp. Cell Res. 181:305-316.
37. Meyerhans, A., J.-P. Vartanian, C. Hultgren, U. Plikat, A. Karlsson, L. Wang, S. Eriksson, and S. Wain-Hobson. 1994. Restriction and enhancement of human immunodeficiency type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:535-540.
38. Milich, L., B. Margolin, and R. Swanstrom. 1993. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J. Virol. 67:5623-5634.
39. Miller, A. D., and C. Buttimore. 1986. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6:2895-2902.
40. Miller, A. D., J. V. Garcia, N. von Suhr, C. M. Lynch, C. Wilson, and M. V. Eiden. 1991. Construction and properties of retrovirus packaging cell lines based on gibbon ape leukemia virus. J. Virol. 65:2220-2224.
41. Parthasarathi, S., A. Varela-Echavarria, Y. Ron, B. D. Preston, and J. P. Dougherty. 1995. Genetic rearrangements occurring during a single cycle of murine leukemia virus vector replication: characterization and implications. J. Virol. 69:7991-8000.
42. Pathak, V. K., and H. M. Temin. 1990. Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc. Natl. Acad. Sci. USA 87:6019-6023.
43. Pathak, V. K., and H. M. Temin. 1990. Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: deletions and deletions with insertions. Proc. Natl. Acad. Sci. USA 87:6024-6028.
44. Pathak, V. K., and H. M. Temin. 1992. 5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate. J. Virol. 66:3093-3100.
45. Patick, A., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hcrmsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P.-F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
46. Preston, B. D., B. J. Poiesz, and L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
47. Reichard, P. 1988. Interactions between deoxyribonucleotide and DNA synthesis. Annu. Rev. Biochem. 57:349-374.
48. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
49. Roe, T., T. C. Reynolds, G. Yu, and P. O. Brown. 1993. Integration of murine leukemia virus depends on mitosis. EMBO J. 12:2099-2108.
50. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
51. Sherman, P. A., and J. A. Fyfe. 1989. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal. Biochem. 180:222-226.
52. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
53. Snyder, R. D. 1988. Consequences of the depletion of cellular deoxynucleoside triphosphate pools on the excision-repair process in cultured human fibroblasts. Mutat. Res. 200:193-199.
54. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in the HIV-1 reverse transcriptase. Science 253:1557-1559.
55. Temin, H. M. 1966. Studies on carcinogenesis by avian sarcoma viruses. V. Requirement for new DNA synthesis and for cell division. J. Cell. Physiol. 69:53-64.
56. Temin, H. M. 1993. Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. Proc. Natl. Acad. Sci. USA 90:6900-6903.
57. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
58. Varela-Echavarria, A., N. Garvey, B. D. Preston, and J. P. Dougherry. 1992. Comparison of Moloney murine leukemia virus mutation rate with the fidelity of its reverse transcriptase in vitro. J. Biol. Chem. 267:24681-24688.
59. Vartanian, J.-P., A. Meyerhans, M. Sala, and S. Wain-Hobson. 1994. G-→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. USA 91:3092-3096.
60. Watanabe, S., and H. M. Temin. 1983. Construction of a helper cell line for reticuioendotheliosis virus cloning vectors. Mol. Cell. Biol. 3:2241-2249.
61. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Sag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
62. Wilkinson, Y. A., and P. G. McKenna. 1989. The effects of thymidme on deoxyribonucleotide pool levels, cytotoxicity and mutation induction on Friend mouse erythroleukemia cells. Leuk. Res. 13:615-620.
63. Yin, P. D., V. K. Pathak, A. E. Rowan, R. J. Teufel II, and W.-S. Hu. 1997. Utilization of nonhomologous minus-strand DNA transfer to generate recombinant retrovimses. J. Virol. 71:2487-2494.
64. Zhang, X., and C. K. Mathews. 1995. Natural DNA precursor pool asymmetry and base sequence context as determinants of replication fidelity. J. Biol. Chem. 270:8401-8404.